The New Biology features long-form discussions with historians, technologists, and scientists working on the biggest ideas in biotechnology, from magnet-controlled medicines to virtual cells.
Nick Desnoyer, a plant biologist in Norwich, England, is designing and creating flowers that don’t exist anywhere in nature. In this interview, he reveals his next project: Paintunia, a petunia that acts as a living canvas. These petunias have an inducible gene; when you lightly touch a bud (before it opens) with a clear molecule, called dexamethasone, that molecules seeps into cells, switches on the gene, and causes them to make a pigment. The result is a paintable flower, where molecules are literally used to control which colors show up in which places. For a prior project, Nick turned…
Pioneer Labs, a nonprofit research group, has engineered a microbe that eats Martian dirt and excretes bioplastic. It is the first step of their "five organism" plan to terraform Mars and make the planet habitable. This interview is with Erika DeBenedictis, the co-founder and CEO of Pioneer Labs. Subscribe to Asimov Press: https://press.asimov.com 0:00 A first microbe engineered for Mars 5:03 Simulating Martian chemistry 8:27 The five "pioneer species" 17:20 Water, warming, and nitrogen 26:39 Radiation, growth rates, and poor measurements 35:49 Starship 41:05 Why create a second biosphere?
Chemists at the University of Minnesota, led by Kate Adamala, recently built a synthetic cell that eats, grows, and divides; purely by putting together molecules in the laboratory. Their creation, called SpudCell, can only divide for five generations. What will it take to make it grow for longer? And why bother making a synthetic cell in the first place? Subscribe to Asimov Press: https://press.asimov.com Chapters: 00:00 SpudCell is not alive 05:16 How SpudCell was made 13:14 How to make a continuously replicating cell 29:48 Finding new mechanisms for cell division 40:38 What is the point of…
A dairy cow is worth $1,000 to $2,000 to a farmer, whereas a broiler chicken, raised for meat, generates just $4 of profit. Quantifying animals this way may feel uncomfortable, but those $4 are all a farmer can spend to keep a chicken healthy. And this places some really interesting constraints on how biotechnology must be scaled (in terms of vaccines and other interventions) in the animal welfare space. In this episode, Robert Yaman, CEO of Innovate Animal Ag, argues that the way to improve animal welfare is to make farming more efficient rather than less. We discuss in-ovo sexing (which…
Scientists have studied bacteria under microscopes for 400 years. But Yonatan Chemla, a postdoctoral fellow at MIT, has developed a technology that lets us see microbes from a drone 100 meters in the air. In this episode, we discuss the emerging field of "hyperspectral biology," which uses hyperspectral cameras (first built by NASA in the 1980s) to detect molecules with unique light-absorption signatures. With this technology, you could engineer a microbe to sense a landmine, for example, and release a pigment in response. A drone could then spot that pigment from hundreds of meters away. By…
Markov Biosciences, a startup in San Francisco, is betting that biology is about to have its GPT moment. In this episode, founder Adam Green explains the "bitter lesson" for biology, the idea borrowed from Richard Sutton that large unbiased datasets and the right training objective tend to outcompete models with hard-coded rules and human priors. Adam thinks, in particular, that the virtual cell field took a wrong turn by spending hundreds of millions of dollars collecting expensive perturbation data. Green’s counterargument is that the data needed to train useful virtual cells is not…
Nonfiction Laboratories is building a technology called “magnetogenetics” that promises to control proteins inside the body — such as antibodies or enzymes — using small magnets. In this episode, co-founder Maria Ingaramo and scientific advisor Andrew York explain how they engineered a protein, MagLOV, that responds strongly to magnetic fields, why most prior attempts have failed to replicate, and how the mechanism of magnetically-controlled proteins actually works. They also get into the “dream” use cases, like cancer drugs that activate only at the tumor, which might have a lower toxicity…
Plasmidsaurus took plasmid sequencing from $600 to $15 and turned a "boring" service company idea into a hugely successful company serving 70,000+ scientists. In this episode, CEO Mark Budde and Niko McCarty get into the bigger question: what does it take for companies to automate and scale wet-lab biology methods in the same way that Plasmidsaurus did for sequencing? They cover the early Oxford Nanopore bet, the obsession with speed, and why Mark won’t sell customer data to AI labs. This podcast is made possible by Astera Institute.
About The New Biology
The New Biology features long-form discussions with historians, technologists, and scientists working on the biggest ideas in biotechnology, from magnet-controlled medicines to virtual cells.
The New Biology is a English tech & science podcast from Niko McCarty. Melo plays each episode straight from the publisher's own feed — no ads added, no account needed — and remembers where you stopped, in this browser only.
The Melo app keeps playing with the screen off, works in the car and on your watch, wakes you to your station, and browses the whole catalogue offline. Free, no ads, no account.
